Abstract
Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.
| Original language | English |
|---|---|
| Journal | JDDG - Journal of the German Society of Dermatology |
| Volume | 17 |
| Issue number | 2 |
| Pages (from-to) | 214-230 |
| Number of pages | 17 |
| ISSN | 1610-0379 |
| DOIs | |
| Publication status | Published - 01.02.2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 9 Industry, Innovation, and Infrastructure
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
Fingerprint
Dive into the research topics of 'S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow-up'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver